Onkure Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
AI Biotechnology LLC, along with affiliated entities and Len Blavatnik, has reported beneficial ownership of 19.99% of OnKure Therapeutics' Class A Common Stock following a private placement and warrant acquisition.
NASDAQ
SCHEDULE 13D/A: Acorn Bioventures Increases Stake in OnKure Therapeutics to Over 22% Following Recent Share Purchase
Acorn Bioventures and its affiliates have significantly increased their beneficial ownership in OnKure Therapeutics, Inc. to 22.1% through recent share acquisitions and a prior merger.
NASDAQ
SCHEDULE 13D: Acorn Bioventures and Anders Hove Disclose Significant Stake in OnKure Therapeutics, Affirming Investment Intent
Investment firms Acorn Bioventures and its affiliates, along with manager Anders Hove, have disclosed a substantial beneficial ownership stake in OnKure Therapeutics, Inc., primarily for investment purposes.
NASDAQ
A group of investment entities and individuals associated with RiverVest Venture Funds has reported ceasing beneficial ownership of more than 5% of OnKure Therapeutics, Inc.'s common stock.